Company Profile
Amylyx Stock Price, News & Analysis
- Ticker:
- AMLX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
24.19 USD (+10.71%)
Close
Last updated: August 6, 2026
1.48B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, AMLX closed up 10.7% at $24.19. No new same-company headline was identified in the current news window.
Company overview
Business overview
Amylyx is a neuroscience company that has shifted after Relyvrio toward a broader rare-disease and neurodegeneration pipeline.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Amylyx sits in specialty neuroscience biotech.
Business Model Characteristics
The company now depends on pipeline execution, data credibility, and rebuilding investor confidence after a major product reset.
Position Within the Biotechnology Landscape
Amylyx remains a headline-sensitive CNS name because the market is still reassessing its long-term story.
Future catalysts
Amylyx's catalysts are AMX0114 and the post-Relyvrio pipeline reset, which need to show the company still has a credible neuroscience path. The next update matters because the story is still being rebuilt.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Amylyx (AMLX)?
Amylyx (AMLX) most recently closed at 24.19 USD, a +10.71% move versus the previous session.
What is the market cap of Amylyx (AMLX)?
Amylyx currently has a market capitalization of 1.48B USD on BioPharmSignal.
What does Amylyx do?
Amylyx is a neuroscience company that has shifted after Relyvrio toward a broader rare-disease and neurodegeneration pipeline.
On which exchange is AMLX stock listed?
Amylyx (AMLX) is associated with NASDAQ, United States, Biopharma.
What is Amylyx?
Amylyx's catalysts are AMX0114 and the post-Relyvrio pipeline reset, which need to show the company still has a credible neuroscience path.
Which conditions is Amylyx targeting with Amylyx?
Amylyx is associated with neuroscience based on its company overview and current catalyst commentary.
How does Amylyx describe recent progress with Amylyx?
Amylyx's catalysts are AMX0114 and the post-Relyvrio pipeline reset, which need to show the company still has a credible neuroscience path.
What is Relyvrio?
Amylyx is a neuroscience company that has shifted after Relyvrio toward a broader rare-disease and neurodegeneration pipeline.